<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523272</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2450-III-07</org_study_id>
    <nct_id>NCT04523272</nct_id>
  </id_info>
  <brief_title>A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer</brief_title>
  <official_title>A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, positive parallel controlled, multicentre phase III clinical&#xD;
      trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib&#xD;
      in subjects with advanced renal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) evaluated by Independent Review Committee(IRC)</measure>
    <time_frame>up to 60 weeks</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on IRC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) evaluated by investigator</measure>
    <time_frame>up to 60 weeks</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 60 weeks</time_frame>
    <description>OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate（DCR）</measure>
    <time_frame>up to 60 weeks</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response（DOR）</measure>
    <time_frame>up to 60 weeks</time_frame>
    <description>The time when the participants first achieved complete or partial remission to disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival at 12 months</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Percentage of participants whose PFS has achieved at least 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 12 months</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Percentage of participants whose OS has achieved at least 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 24 months</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Percentage of participants whose OS has achieved at least 24 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">418</enrollment>
  <condition>Advanced Renal Cancer</condition>
  <arm_group>
    <arm_group_label>TQB2450 + Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sunitinib Malate Capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sunitinib malate capsule 50mg administered orally, once daily in 28-day cycle(14 days on treatment from Day 1-14, 14 days off treatment from day 15-28).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450</intervention_name>
    <description>TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.</description>
    <arm_group_label>TQB2450 + Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>A multi-target receptor tyrosine kinase inhibitor.</description>
    <arm_group_label>TQB2450 + Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>A multi-target receptor tyrosine kinase inhibitor.</description>
    <arm_group_label>Sunitinib Malate Capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Histopathologically confirmed renal clear cell cancer, including advanced renal&#xD;
             cell carcinoma with clear cell components.&#xD;
&#xD;
             2. Has not receiving systemic therapy for local advanced/metastatic disease. 3. At&#xD;
             least has one measurable lesion. 4. Eastern Cooperative Oncology Group (ECOG)&#xD;
             performance status of 0 to 1; Life expectancy ≥ 3 months.&#xD;
&#xD;
             5. Adequate laboratory indicators. 6. Agree to provide at least 5 slices tumor tissue&#xD;
             samples for biomarker detection.&#xD;
&#xD;
             7. Serum or urine pregnancy tests are negative within 7 days before randomization; Men&#xD;
             and women should agree to use effective contraception during the study period and&#xD;
             after the end of the study period within 6 months.&#xD;
&#xD;
             8. Understood and signed an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Has symptomatic central nervous system (CNS) disease and / or cancerous meningitis,&#xD;
             pia mater disease.&#xD;
&#xD;
             2. Has received anti-angiogenesis targeted therapy or targeted PD-1 and PD-L1&#xD;
             immunotherapy.&#xD;
&#xD;
             3. Has active virus, bacteria, fungal infection; Cardiovascular and cerebrovascular&#xD;
             diseases; Gastrointestinal abnormalities; Immunodeficiency; Bleeding risk; Lung&#xD;
             disease; Neurological or psychiatric disorders.&#xD;
&#xD;
             4. Has participated in other clinical trials within 30 days before randomization.&#xD;
&#xD;
             5. Has received attenuated live vaccine within 28 days before randomization or planned&#xD;
             to received attenuated live vaccine during the study period.&#xD;
&#xD;
             6. Pregnant or lactating women. 7. According to the judgement of the investigators,&#xD;
             there are other factors that may lead to the termination of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Guo, Doctor</last_name>
    <phone>010-88196348</phone>
    <email>guo307@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230601</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dexin Yu, Master</last_name>
      <email>yudx_urology@126.com</email>
    </contact>
    <investigator>
      <last_name>Dexin Yu, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aiping Zhou, Doctor</last_name>
      <phone>010-87788800</phone>
      <email>zhouap1825@126.com</email>
    </contact>
    <investigator>
      <last_name>Aiping Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaofeng Zhou, Doctor</last_name>
      <email>dzsfighting@126.com</email>
    </contact>
    <investigator>
      <last_name>Xiaofeng Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhigang Ji</last_name>
      <email>jizhigang@pumch.cn</email>
    </contact>
    <investigator>
      <last_name>Zhigang Ji</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhisong He</last_name>
      <email>wyj7074@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Zhisong He</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Guo, Doctor</last_name>
      <phone>010-88196348</phone>
      <email>guo307@126.com</email>
    </contact>
    <investigator>
      <last_name>Jun Guo, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lulin Ma</last_name>
      <email>malulin901@126.com</email>
    </contact>
    <investigator>
      <last_name>Lulin Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shunchang Jiao, Doctor</last_name>
      <email>jiaosc@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Shunchang Jiao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Li</last_name>
      <email>596363075@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yuan Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tongjian Cui, Master</last_name>
      <email>fjslctj@163.com</email>
    </contact>
    <investigator>
      <last_name>Tongjian Cui, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen of Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fangjian Zhou, Doctor</last_name>
      <email>zhoufj@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Fangjian Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Tumor Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jin Wu, Doctor</last_name>
      <email>w.u_jin@163.com</email>
    </contact>
    <investigator>
      <last_name>Jin Wu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weiqing Han</last_name>
      <email>md70210@sina.com</email>
    </contact>
    <investigator>
      <last_name>Weiqing Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongqian Guo, Doctor</last_name>
      <email>gymwpi@126.com</email>
    </contact>
    <investigator>
      <last_name>Hongqian Guo, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangxi Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinhua Tu</last_name>
      <email>zhou629812@163.com</email>
    </contact>
    <investigator>
      <last_name>Xinhua Tu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ziling Liu, Doctor</last_name>
      <email>drzilingliu@163.com</email>
    </contact>
    <investigator>
      <last_name>Ziling Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116027</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Man Li, Doctor</last_name>
      <email>dyeyliman@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Man Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheng Fu</last_name>
      <email>13840219900@163.com</email>
    </contact>
    <investigator>
      <last_name>Cheng Fu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benkang Shi, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Benkang Shi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tenth People's Hospital of Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xudong Yao, Doctor</last_name>
      <email>yaoxudong67@sina.com</email>
    </contact>
    <investigator>
      <last_name>Xudong Yao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of PLA Air Force Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>711400</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weijun Qin, Doctor</last_name>
      <email>qinweij@fmmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Weijun Qin, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pengfei Shen, Doctor</last_name>
      <email>cdhx510@163.com</email>
    </contact>
    <investigator>
      <last_name>Pengfei Shen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiubao Ren, Doctor</last_name>
      <email>renxiubao@tjmuch.com</email>
    </contact>
    <investigator>
      <last_name>Xiubao Ren, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital,School of Medicine,Shihezi University</name>
      <address>
        <city>Shihezi</city>
        <state>Xinjiang</state>
        <zip>832008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ping Gong, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Ping Gong, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peng Chen, Master</last_name>
      <email>chenpeng9@126.com</email>
    </contact>
    <investigator>
      <last_name>Peng Chen, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of The University of Chinese Academy of Sciences</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shaoxing Zhu, Doctor</last_name>
      <email>zsxing2005@126.com</email>
    </contact>
    <investigator>
      <last_name>Shaoxing Zhu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

